0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Malignant Pheochromocytoma: Effective Treatment with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine

Steven D. Averbuch, MD; Caryn S. Steakley, RN; Robert C. Young, MD; Edward P. Gelmann, MD; David S. Goldstein, MD, PhD; Robin Stull, BS; and Harry R. Keiser, MD
[+] Article and Author Information

Presented in part 19 May 1987 at the Twenty-Third Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia.

Requests for Reprints: Steven D. Averbuch, MD, Department of Neoplastic Diseases, Box 1129, The Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029.

Current Author Addresses: Dr. Averbuch: Department of Neoplastic Diseases, Box 1129, The Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029.

Ms. Steakley and Dr. Gelmann: Medicine Branch, National Cancer Institute, Building 10, Room 12N226, National Institutes of Health, Bethesda, MD 20892.

Dr. Young: CCOP, National Cancer Institute, Blair Building, Room 732, Bethesda, MD 20892-4200.

Drs. Goldstein, Stull, and Keiser: Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, Building 10, Room 1C103, National Institutes of Health, Bethesda, MD 20892.


Ann Intern Med. 1988;109(4):267-273. doi:10.7326/0003-4819-109-4-267
Text Size: A A A

Study Objective: To determine the efficacy and toxicity of combination chemotherapy in patients with advanced, malignant pheochromocytoma.

Design: Nonrandomized, single-arm trial.

Setting: Governmental medical referral center.

Patients: Fourteen patients with malignant pheochromocytoma confirmed by histologic tests. All patients had metastatic disease and elevated urinary catecholamine secretion.

Interventions: After optimization of antihypertensive therapy, patients received cyclophosphamide, 750 mg/m2 body surface area on day 1; vincristine, 1.4 mg/m2 on day 1, and dacarbazine, 600 mg/m2 on days 1 and 2, every 21 days.

Measurements and Main Results: Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine produced a complete and partial response rate of 57% (median duration, 21 months; range, 7 to more than 34). Complete and partial biochemical responses were seen in 79% of patients (median duration, more than 22 months; range, 6 to more than 35). All responding patients had objective improvement in performance status and blood pressure. Toxicity included expected hematologic, neurologic, and gastrointestinal effects of chemotherapy without serious sequelae. There were four minor hypotensive episodes and one minor hypertensive episode.

Conclusions: Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine is effective for advanced malignant pheochromocytoma. Urinary catecholamines are useful to ascertain biochemical response to therapy.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)